These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 17109975

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase by a stavudine analogue, 4'-ethynyl stavudine triphosphate.
    Yang G, Wang J, Cheng Y, Dutschman GE, Tanaka H, Baba M, Cheng YC.
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2035-42. PubMed ID: 18391035
    [Abstract] [Full Text] [Related]

  • 3. Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.
    Yang G, Paintsil E, Dutschman GE, Grill SP, Wang CJ, Wang J, Tanaka H, Hamasaki T, Baba M, Cheng YC.
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4640-6. PubMed ID: 19704131
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Balancing antiviral potency and host toxicity: identifying a nucleotide inhibitor with an optimal kinetic phenotype for HIV-1 reverse transcriptase.
    Sohl CD, Kasiviswanathan R, Kim J, Pradere U, Schinazi RF, Copeland WC, Mitsuya H, Baba M, Anderson KS.
    Mol Pharmacol; 2012 Jul; 82(1):125-33. PubMed ID: 22513406
    [Abstract] [Full Text] [Related]

  • 6. Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro.
    Nitanda T, Wang X, Kumamoto H, Haraguchi K, Tanaka H, Cheng YC, Baba M.
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3355-60. PubMed ID: 16048947
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase.
    Gao HQ, Boyer PL, Sarafianos SG, Arnold E, Hughes SH.
    J Mol Biol; 2000 Jul 07; 300(2):403-18. PubMed ID: 10873473
    [Abstract] [Full Text] [Related]

  • 10. Mechanism of inhibition of the human immunodeficiency virus type 1 reverse transcriptase by d4TTP: an equivalent incorporation efficiency relative to the natural substrate dTTP.
    Vaccaro JA, Parnell KM, Terezakis SA, Anderson KS.
    Antimicrob Agents Chemother; 2000 Jan 07; 44(1):217-21. PubMed ID: 10602755
    [Abstract] [Full Text] [Related]

  • 11. Partial selective inhibition of HIV-1 reverse transcriptase and human DNA polymerases γ and β by thiated 3'-fluorothymidine analogue 5'-triphosphates.
    Wińska P, Miazga A, Poznański J, Kulikowski T.
    Antiviral Res; 2010 Nov 07; 88(2):176-81. PubMed ID: 20739003
    [Abstract] [Full Text] [Related]

  • 12. Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities.
    Shaw-Reid CA, Feuston B, Munshi V, Getty K, Krueger J, Hazuda DJ, Parniak MA, Miller MD, Lewis D.
    Biochemistry; 2005 Feb 08; 44(5):1595-606. PubMed ID: 15683243
    [Abstract] [Full Text] [Related]

  • 13. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine.
    de Muys JM, Gourdeau H, Nguyen-Ba N, Taylor DL, Ahmed PS, Mansour T, Locas C, Richard N, Wainberg MA, Rando RF.
    Antimicrob Agents Chemother; 1999 Aug 08; 43(8):1835-44. PubMed ID: 10428900
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Three-drug combinations of emivirine and nucleoside reverse transcriptase inhibitors in vitro: long-term culture of HIV-1-infected cells and breakthrough viruses.
    Nitanda T, Wang X, Somekawa K, Yuasa S, Baba M.
    Antivir Chem Chemother; 2001 May 08; 12(3):161-7. PubMed ID: 12959324
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL, Ahmed PS, Tyms AS, Wood LJ, Kelly LA, Chambers P, Clarke J, Bedard J, Bowlin TL, Rando RF.
    Antivir Chem Chemother; 2000 Jul 08; 11(4):291-301. PubMed ID: 10950391
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.